Blurbs

Analysts Offer Insights on Healthcare Companies: Amicus (FOLD), Cardinal Health (CAH) and Nektar Therapeutics (NKTR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amicus (FOLDResearch Report), Cardinal Health (CAHResearch Report) and Nektar Therapeutics (NKTRResearch Report).

Amicus (FOLD)

In a report issued on August 11, Anupam Rama from J.P. Morgan maintained a Buy rating on Amicus, with a price target of $16.00. The company’s shares closed last Monday at $12.37, close to its 52-week high of $12.76.

According to TipRanks.com, Rama is a 4-star analyst with an average return of 3.8% and a 47.0% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Springworks Therapeutics, and Apellis Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amicus with a $14.25 average price target, which is a 16.9% upside from current levels. In a report issued on August 5, SVB Securities also reiterated a Buy rating on the stock with a $16.00 price target.

See today’s best-performing stocks on TipRanks >>

Cardinal Health (CAH)

In a report issued on August 12, Lisa Gill from J.P. Morgan maintained a Hold rating on Cardinal Health, with a price target of $68.00. The company’s shares closed last Monday at $69.97, close to its 52-week high of $71.45.

According to TipRanks.com, Gill is a 5-star analyst with an average return of 17.4% and a 66.3% success rate. Gill covers the Healthcare sector, focusing on stocks such as Alignment Healthcare, Privia Health Group, and Option Care Health.

Currently, the analyst consensus on Cardinal Health is a Hold with an average price target of $67.00, implying a -2.7% downside from current levels. In a report issued on August 11, Mizuho Securities also maintained a Hold rating on the stock with a $66.00 price target.

Nektar Therapeutics (NKTR)

Nektar Therapeutics received a Sell rating from J.P. Morgan analyst Jessica Fye yesterday. The company’s shares closed last Monday at $4.91, close to its 52-week low of $3.02.

According to TipRanks.com, Fye is a 4-star analyst with an average return of 10.8% and a 56.5% success rate. Fye covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Crinetics Pharmaceuticals, and Intra-Cellular Therapies.

Nektar Therapeutics has an analyst consensus of Hold, with a price target consensus of $4.74.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on FOLD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos